Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Intensity Therapeutics / IT-03

Trial Overview

Official Title

A Multicenter, Randomized, Phase III Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With Standard of Care in Adult participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL)

 

Study Purpose

To evaluate the effectiveness of IT-03 compared to the usual treatment of pazopanib, trabectedin or eribulin

 

Diagnosis

Non-uterine leiomyosarcoma; liposarcoma; or pleomorphic sarcoma

Eligibility

Locally recurrent, inoperable or metastatic with disease progression following one to two prior regimens of treatment. 

 

Intervention

Experimental arm: Tumor injected INT230-6 by interventional radiologist

Control arm: standard of care (usual treatment) – pazopanib, trabectedin or eribulin

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT06263231?term=Intensity%20Therapeutics%20IT-03&rank=1

 

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Male or Female
Age
18 years and Older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
IT-03